Astrazeneca Ditics plans to build a new vaccine factory in the United Kingdom

Digest opened free editor

Rola Khaleda, FT editor, chooses her favorite stories in this weekly newsletter.

Astrazneca graduated from its plans to build a factory to manufacture UK vaccines worth 450 million pounds after months of quarrels with British officials about the state’s investment of the Mercyside project, in a major blow to the government of Prime Minister Sir Kiir Starmer.

The officials made a revised offer for the financial support of the site at Speke this month, which was much higher than 40 million pounds, and said people who have knowledge of arrangements.

Last summer, the STARMER Labor Party government sought to reduce the amount of state support to the project from about 90 million pounds to 40 million pounds, according to the people who were briefed on this.

“After long discussions with the government, we no longer follow our planned investments in Speke,” Astrazneca said in a statement on Friday. “Several factors have affected this decision, including timing and reducing the final offer compared to the proposal of the previous government.”

The company said that the current Speke site will continue to produce and provide the influenza vaccine.

The people said that the previous offer made by the former conservative adviser Jeremy Hunt included up to 70 million pounds in grants to develop the current Astrazneca vaccine facility in Speke, in addition to 20 million pounds as support for research and development from the UK Health Security Agency.

The Treasury did not immediately respond to the request for comment.